CAMX.ST Stock - Camurus AB (publ)
Unlock GoAI Insights for CAMX.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.87B | $1.72B | $956.34M | $600.57M | $336.00M |
| Gross Profit | $1.74B | $1.59B | $853.08M | $515.22M | $300.71M |
| Gross Margin | 93.1% | 92.9% | 89.2% | 85.8% | 89.5% |
| Operating Income | $469.17M | $532.36M | $71.96M | $-112,357,000 | $-206,569,000 |
| Net Income | $428.39M | $431.44M | $55.55M | $-90,446,000 | $-167,265,000 |
| Net Margin | 22.9% | 25.1% | 5.8% | -15.1% | -49.8% |
| EPS | $7.39 | $7.78 | $1.01 | $-1.66 | $-3.18 |
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Visit WebsiteEarnings History & Surprises
CAMX.STEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | $3.28 | $3.19 | -2.7% | ✗ MISS |
Q3 2025 | Jul 17, 2025 | $3.81 | $4.08 | +7.1% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $2.82 | $3.23 | +14.5% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $1.54 | $2.45 | +59.1% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $1.46 | $2.16 | +47.9% | ✓ BEAT |
Q3 2024 | Jul 16, 2024 | $1.40 | $1.25 | -10.7% | ✗ MISS |
Q2 2024 | May 8, 2024 | $1.12 | $1.32 | +17.9% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $0.91 | $-0.27 | -129.7% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $0.82 | $1.50 | +82.9% | ✓ BEAT |
Q3 2023 | Jul 18, 2023 | $5.73 | $5.24 | -8.6% | ✗ MISS |
Q2 2023 | May 10, 2023 | $0.45 | $1.02 | +126.7% | ✓ BEAT |
Q1 2023 | Feb 14, 2023 | $0.29 | $0.23 | -20.7% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $0.14 | $0.63 | +350.0% | ✓ BEAT |
Q3 2022 | Jul 15, 2022 | $-0.24 | $0.14 | +158.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.26 | $-0.01 | +96.2% | ✓ BEAT |
Q1 2022 | Feb 16, 2022 | $-0.32 | $-0.26 | +18.8% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | — | $-0.11 | — | — |
Q3 2021 | Jul 15, 2021 | $-0.52 | $-0.89 | -71.2% | ✗ MISS |
Latest News
Frequently Asked Questions about CAMX.ST
What is CAMX.ST's current stock price?
What is the analyst price target for CAMX.ST?
What sector is Camurus AB (publ) in?
What is CAMX.ST's market cap?
Does CAMX.ST pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CAMX.ST for comparison